HBPCF (Helix BioPharma) Debt-to-Equity : 0.00 (As of Jul. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Helix BioPharma Debt-to-Equity?

Helix BioPharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2024 was $0.00 Mil. Helix BioPharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jul. 2024 was $0.00 Mil. Helix BioPharma's Total Stockholders Equity for the quarter that ended in Jul. 2024 was $-0.07 Mil. Helix BioPharma's debt to equity for the quarter that ended in Jul. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Helix BioPharma's Debt-to-Equity or its related term are showing as below:

During the past 13 years, the highest Debt-to-Equity Ratio of Helix BioPharma was 7.74. The lowest was -2.59. And the median was 0.07.

HBPCF's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Helix BioPharma Debt-to-Equity Historical Data

The historical data trend for Helix BioPharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma Debt-to-Equity Chart

Helix BioPharma Annual Data

Trend

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

Debt-to-Equity

Get a 7-Day Free Trial

0.07

-2.59

7.73

Helix BioPharma Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Helix BioPharma's Debt-to-Equity

For the Biotechnology subindustry, Helix BioPharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Helix BioPharma's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helix BioPharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Helix BioPharma's Debt-to-Equity falls into.

Helix BioPharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Helix BioPharma's Debt to Equity Ratio for the fiscal year that ended in Jul. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	-0.066
	=	0.00

Helix BioPharma's Debt to Equity Ratio for the quarter that ended in Jul. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	-0.066
	=	0.00

Helix BioPharma (OTCPK:HBPCF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Helix BioPharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Helix BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (OTCPK:HBPCF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

HBP0:Germany HBP:Canada

Address

40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4

Website

https://www.helixbiopharma.com

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.